Source comparison
TB-500 Research Neurological Considerations: Protocol Comparison
Acute Neuroprotection (Stroke/TBI) Within 6 hours post-injury, daily × 7 days Intravenous or intraperitoneal 10–15% of plasma concentration Infarct volume, lesion size, motor function scores at 72h and 28d TB-500 shows strongest efficacy when initiated immedia
This comparison does not assign a generated winner or score.
- Acute Neuroprotection (Stroke/TBI)
- Within 6 hours post-injury, daily × 7 days
- Intravenous or intraperitoneal
- 10–15% of plasma concentration
- Infarct volume, lesion size, motor function scores at 72h and 28d
- TB-500 shows strongest efficacy when initiated immediately post-injury. Delayed administration (>24h) reduces neuroprotective benefit by ~60%
- Axonal Regeneration (Spinal Cord Injury)
- Days 1–14 post-injury, every 48 hours
- Subcutaneous preferred for sustained release
- 8–12% steady-state CNS concentration
- GAP-43 expression, axon density in lesion site, electrophysiological conduction
- Subcutaneous dosing produces more consistent axonal growth than IV bolus due to sustained actin sequestration. Critical during the growth cone extension phase
- Chronic Neurodegenerative Models
- Continuous administration, every 72 hours
- Subcutaneous
- 8–10% baseline CNS presence
- BDNF levels, microglial phenotype (M1/M2 ratio), behavioral cognitive testing
- TB-500's effects on chronic neurodegeneration are modest compared to acute injury. Best used as part of multi-pathway intervention rather than monotherapy
- Neuroplasticity Enhancement (Learning/Memory)
- Pre-treatment + post-learning consolidation
- Intranasal or subcutaneous
- 12–18% with intranasal delivery
- Novel object recognition, Morris water maze latency, synaptic density markers
- Intranasal administration bypasses first-pass metabolism and delivers higher CNS concentrations. Most effective for behavioral plasticity studies without acute injury context